Anti-Tim-3 Antibodies Persistent Receptor Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack an effective and specific anti-Tim-3 antibody that can persistently internalize the Tim-3 receptor, leading to inadequate modulation of Tim-3-mediated immune suppression in cancers and chronic viral infections.
Innovation Solution
Development of antibodies with high affinity and specificity for Tim-3, capable of persistent internalization, which are used alone or in combination with other therapeutic agents to treat immune disorders, cancers, and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target Tim-3, then some level of binding is achieved, but persistent internalization of the Tim-3 receptor does not occur, resulting in inadequate modulation of immune suppression
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's affinity parameters and binding characteristics to achieve persistent internalization. The anti-Tim-3 antibody is engineered with optimized complementarity determining regions (CDRs) that specifically bind to Tim-3 with high affinity, triggering sustained receptor internalization. This parameter optimization resolves the contradiction by transforming a transient binding interaction into a persistent internalization process, thereby achieving reliable and durable modulation of Tim-3-mediated immune suppression.
2Force
If high affinity antibodies are developed, then binding strength to Tim-3 is improved, but specificity and avoidance of off-target effects becomes more difficult to maintain
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the antibody molecule, particularly the complementarity determining regions (CDRs), to achieve high affinity binding to Tim-3 while maintaining specificity. The antibody structure is locally refined in the antigen-binding sites to recognize unique epitopes on Tim-3, while the rest of the molecule maintains properties that prevent off-target binding. This localized optimization resolves the contradiction by concentrating binding strength at the target interface without compromising overall specificity.
Solution Approach 2:
The patent employs feedback mechanisms through iterative antibody engineering and selection processes. Multiple rounds of affinity maturation and specificity testing are performed, where binding characteristics are measured and used to guide further optimization. This feedback loop ensures that high affinity is achieved while simultaneously monitoring and eliminating off-target effects, resolving the contradiction between binding strength and specificity.
3Productivity
If Tim-3 signaling is blocked, then T-cell exhaustion is reduced and immune response is enhanced, but the complexity of therapeutic regimens increases when combining with other checkpoint inhibitors
Solution Approach 1:
The patent applies universality by designing the anti-Tim-3 antibody to function as a standalone therapeutic agent that can effectively block Tim-3 signaling and activate immune responses without requiring complex combination regimens. The antibody is engineered to have multiple functional capabilities: high affinity binding, persistent internalization, and effective immune modulation, allowing it to achieve therapeutic effects as a monotherapy or in simplified combination regimens. This multi-functionality resolves the contradiction by reducing the need for complex multi-agent therapies while maintaining or enhancing immune response activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit Tim-3-mediated signaling, re-activate immune cells, and enhance immunity, demonstrating therapeutic potential in treating various diseases associated with immune tolerance and exhaustion.
Implementation Method 1
antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3)
Implementation Method 2
capable of persistent internalization
Implementation Method 3
The antibodies effectively inhibit Tim-3-mediated signaling
Implementation Method 4
re-activate immune cells, and enhance immunity
Data Source
Figure 1~2A
Figure 2B~3
Figure 4~5
AI summary
Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.